News

21.01.22 Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models

10.12.21 Medannex’s new therapy shows powerful synergy with common cancer treatments

10.09.21 Medannex team leads the field in BIA charity fundraiser

15.04.21 Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021

25.03.21 Medannex sweeps the board at Scotland’s Life Sciences Annual Awards

05.01.21 Medannex team grows to 12 employees, as preparations for First-in-Human study gather pace